Rigel Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RIGL)

$3.73 +0.03 (+0.81 %)
(As of 02/25/2018 04:30 AM ET)
Previous Close$3.73
Today's Range$3.62 - $3.78
52-Week Range$2.14 - $4.71
Volume609,009 shs
Average Volume1.25 million shs
Market Capitalization$550.84 million
P/E Ratio-6.32
Dividend YieldN/A
Beta1.29

About Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals logoRigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The Company’s clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted a new drug application (NDA) to the United States food and drug administration (FDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, the Company has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. The Company is engaged in conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:RIGL
CUSIP76655960
Phone+1-650-6241100

Debt

Debt-to-Equity RatioN/A
Current Ratio4.64%
Quick Ratio4.64%

Price-To-Earnings

Trailing P/E Ratio-6.32203389830508
Forward P/E Ratio-6.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.38 million
Price / Sales26.81
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book6.66

Profitability

Trailing EPS($0.59)
Net Income$-69,210,000.00
Net MarginsN/A
Return on Equity-102.26%
Return on Assets-80.57%

Miscellaneous

Employees77
Outstanding Shares146,490,000

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The biotechnology company had revenue of $0.90 million for the quarter. Rigel Pharmaceuticals's quarterly revenue was down 76.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.24) EPS. View Rigel Pharmaceuticals' Earnings History.

When will Rigel Pharmaceuticals make its next earnings announcement?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Rigel Pharmaceuticals.

Where is Rigel Pharmaceuticals' stock going? Where will Rigel Pharmaceuticals' stock price be in 2018?

5 brokerages have issued 12-month target prices for Rigel Pharmaceuticals' stock. Their predictions range from $5.00 to $7.00. On average, they anticipate Rigel Pharmaceuticals' share price to reach $5.80 in the next year. View Analyst Ratings for Rigel Pharmaceuticals.

What are Wall Street analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "Commercial in 2018. Fostamatinib has a PDUFA date of April 17, 2018 for its application in ITP. With over 5,000 patient-years of treatment experience and a robust Phase 3 clinical package, we anticipate a positive decision in April. Rigel has begun pre-commercial activities for a potential launch and outlined its plans for a full commercial team of 50-60 individuals. Based on the mixed efficacy of currently available treatments, fragmentation of the therapeutic landscape, and concentration of prescribing physicians (3,000 hematologists and hematologist- oncologists), we believe Rigel will be successful at commercializing the drug." (12/14/2017)
  • 2. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (11/11/2017)
  • 3. Jefferies Group LLC analysts commented, "RIGL is on track to submit an NDA for fosta in ITP in 1Q17; next major catalyst could be FDA acceptance by ~May given mixed Ph3 data & limited FDA interactions following Ph3 data. YE16 cash of ~$75M, plus net proceeds of $43M from recent offering, should be sufficient at least for next 12 months including pre-commercial activities, per RIGL. If fosta is approved in ITP, we see >50% upside to our current PT of $5." (3/8/2017)
  • 4. BMO Capital Markets analysts commented, "We remain focused on fostamatinib's pending NDA submission, which we believe supports approval given clear and consistent benefit in ITP, despite one pivotal trial missing statistical significance. We believe reaching an FDA Adcom would be a positive event, as a panel of clinicians would likely recommend approval. Additionally, we believe the fostamatinib addressable patient population is larger than the 18% stable response rate, as real world use would include patients who maintain platelet counts greater than 30K/ul, according to physician feedback. We rate RIGL shares Outperform." (3/8/2017)

Who are some of Rigel Pharmaceuticals' key competitors?

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the folowing people:

  • Raul R Rodriguez, President, Chief Executive Officer, Director (Age 55)
  • Dolly A. Vance, Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary (Age 50)
  • Eldon C. Mayer III, Executive Vice President, Chief Commercial Officer
  • Anne-Marie Duliege M.D., Chief Marketing Officer (Age 54)
  • Nelson Cabatuan, Interim Principal Accounting (Age 40)
  • Keith A. Katkin, Director (Age 44)
  • Brian L. Kotzin M.D., Director
  • Gregg Lapointe, Director
  • Bradford S. Goodwin, Independent Director (Age 60)
  • Gary A. Lyons, Independent Director (Age 66)

Who owns Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.66%), Millennium Management LLC (3.81%), Palo Alto Investors LLC (2.69%), Rock Springs Capital Management LP (1.69%), Geode Capital Management LLC (0.85%) and Candriam Luxembourg S.C.A. (0.83%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Donald G Payan and Ryan D Maynard. View Institutional Ownership Trends for Rigel Pharmaceuticals.

Who sold Rigel Pharmaceuticals stock? Who is selling Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Metropolitan Life Insurance Co. NY, Candriam Luxembourg S.C.A., B. Riley Financial Inc. and Rhumbline Advisers. Company insiders that have sold Rigel Pharmaceuticals company stock in the last year include Anne-Marie Duliege and Ryan D Maynard. View Insider Buying and Selling for Rigel Pharmaceuticals.

Who bought Rigel Pharmaceuticals stock? Who is buying Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Rock Springs Capital Management LP, Deutsche Bank AG, EAM Investors LLC, Renaissance Technologies LLC, Bain Capital Public Equity Management LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Rigel Pharmaceuticals.

How do I buy Rigel Pharmaceuticals stock?

Shares of Rigel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of Rigel Pharmaceuticals stock can currently be purchased for approximately $3.73.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $550.84 million and generates $20.38 million in revenue each year. The biotechnology company earns $-69,210,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Rigel Pharmaceuticals employs 77 workers across the globe.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 Veterans Blvd, SOUTH SAN FRANCISCO, CA 94080-1985, United States. The biotechnology company can be reached via phone at +1-650-6241100 or via email at [email protected]


MarketBeat Community Rating for Rigel Pharmaceuticals (RIGL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  386
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rigel Pharmaceuticals (NASDAQ:RIGL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.80$5.80$5.67$6.75
Price Target Upside: 44.64% upside41.81% upside46.05% upside142.81% upside

Rigel Pharmaceuticals (NASDAQ:RIGL) Consensus Price Target History

Price Target History for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ:RIGL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2018HC WainwrightReiterated RatingBuy$7.00LowView Rating Details
12/21/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$6.00LowView Rating Details
12/14/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$6.00HighView Rating Details
10/4/2017Jefferies GroupReiterated RatingBuy$5.00MediumView Rating Details
10/2/2017BMO Capital MarketsReiterated RatingBuy$5.00LowView Rating Details
8/3/2016JPMorgan Chase & Co.Reiterated RatingBuy$5.00N/AView Rating Details
4/23/2016Credit Suisse GroupUpgradeBuyN/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Rigel Pharmaceuticals (NASDAQ:RIGL) Earnings History and Estimates Chart

Earnings by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ RIGL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018($0.13)N/AView Earnings Details
11/7/2017Q3 2017($0.15)($0.14)$0.90 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.15)($0.16)$2.05 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.12)($0.13)$4.30 million$3.58 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.17)($0.16)$4.25 million$3.00 millionViewListenView Earnings Details
11/1/2016Q316($0.23)($0.24)$3.97 million$3.76 millionViewListenView Earnings Details
8/2/2016Q216($0.20)($0.15)$3.75 million$8.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.19)($0.19)$4.00 million$5.03 millionViewListenView Earnings Details
3/8/2016Q415($0.14)($0.14)$8.90 million$8.50 millionViewListenView Earnings Details
11/3/2015Q315($0.17)($0.08)$5.00 million$12.90 millionViewListenView Earnings Details
8/4/2015Q215($0.22)($0.16)$2.67 million$5.18 millionViewListenView Earnings Details
5/7/2015Q414($0.18)($0.21)$16.00 million$2.18 millionViewListenView Earnings Details
3/3/2015Q4($0.27)($0.25)$2.50 million$8.25 millionViewN/AView Earnings Details
11/4/2014Q314($0.27)($0.24)$1.70 millionViewN/AView Earnings Details
8/5/2014Q214($0.25)($0.29)$1.05 millionViewN/AView Earnings Details
5/7/2014Q114($0.25)($0.25)$0.43 millionViewN/AView Earnings Details
3/4/2014Q4 13($0.25)($0.19)$5.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.29)($0.27)$260.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.30)($0.26)$0.53 million$1.40 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.30)($0.29)$1.73 millionViewN/AView Earnings Details
3/5/2013Q4 2012($0.32)($0.30)ViewN/AView Earnings Details
11/6/2012Q312($0.38)($0.36)$0.84 millionViewN/AView Earnings Details
8/7/2012($0.34)($0.35)ViewN/AView Earnings Details
5/1/2012($0.33)($0.32)ViewN/AView Earnings Details
3/6/2012($0.28)($0.36)ViewN/AView Earnings Details
11/1/2011($0.28)($0.25)ViewN/AView Earnings Details
8/2/2011($0.36)($0.37)ViewN/AView Earnings Details
5/3/2011($0.36)($0.40)ViewN/AView Earnings Details
3/1/2011Q4 2010($0.36)($0.33)ViewN/AView Earnings Details
11/2/2010Q3 2010$0.58$0.96ViewN/AView Earnings Details
8/3/2010Q2 2010$0.45$0.52ViewN/AView Earnings Details
5/4/2010Q1 2010($0.06)($0.43)ViewN/AView Earnings Details
3/2/2010Q4 2009($0.45)($0.48)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.56)($0.70)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.80)($0.81)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.97)($0.80)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.96)($0.91)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.75)($1.03)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.66)($0.93)ViewN/AView Earnings Details
5/6/2008Q1 2008($0.58)($0.79)ViewN/AView Earnings Details
2/12/2008Q4 2007($0.44)($0.61)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Rigel Pharmaceuticals (NASDAQ:RIGL) Earnings Estimates

2018 EPS Consensus Estimate: ($0.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.13)($0.13)($0.13)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.14)($0.14)($0.14)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Rigel Pharmaceuticals (NASDAQ:RIGL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Rigel Pharmaceuticals (NASDAQ RIGL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.21%
Institutional Ownership Percentage: 84.18%
Insider Trades by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)
Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ RIGL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/3/2017Ryan D MaynardCFOSell100,000$3.90$390,000.00100,000View SEC Filing  
7/5/2017Anne-Marie DuliegeInsiderSell5,000$2.69$13,450.00View SEC Filing  
8/30/2016Donald G PayanEVPSell5,303$4.00$21,212.00View SEC Filing  
4/1/2015Donald G PayanEVPSell10,000$3.75$37,500.00View SEC Filing  
12/18/2014Dolly VanceEVPSell1,000$2.22$2,220.00View SEC Filing  
9/3/2014Donald G PayanEVPSell20,000$2.56$51,200.00View SEC Filing  
11/19/2013Bvf Partners P/Ilmajor shareholderSell484,622$2.64$1,279,402.08View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy32,700$3.47$113,469.00View SEC Filing  
9/13/2012Dolly VanceEVPSell4,151$10.43$43,294.93View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Rigel Pharmaceuticals (NASDAQ RIGL) News Headlines

Source:
DateHeadline
Rigel Pharmaceuticals (RIGL) Cut to "Hold" at BidaskClubRigel Pharmaceuticals (RIGL) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - February 24 at 10:22 PM
Rigel Pharmaceuticals, Inc. (RIGL) Given Consensus Rating of "Buy" by BrokeragesRigel Pharmaceuticals, Inc. (RIGL) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 24 at 3:02 PM
Rigel Pharmaceuticals (RIGL) Upgraded to "Buy" at BidaskClubRigel Pharmaceuticals (RIGL) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - February 11 at 9:10 PM
Rigel Pharmaceuticals (RIGL) vs. Kindred Biosciences (KIN) Critical AnalysisRigel Pharmaceuticals (RIGL) vs. Kindred Biosciences (KIN) Critical Analysis
www.americanbankingnews.com - February 9 at 12:44 PM
Rigel Pharmaceuticals (RIGL) Earns "Buy" Rating from HC WainwrightRigel Pharmaceuticals (RIGL) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - February 2 at 9:08 AM
Rigel Pharmaceuticals (RIGL) Stock Rating Lowered by BidaskClubRigel Pharmaceuticals (RIGL) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - January 31 at 10:24 PM
Rigel Pharmaceuticals, Inc. (RIGL) Given Consensus Recommendation of "Buy" by AnalystsRigel Pharmaceuticals, Inc. (RIGL) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 30 at 11:48 AM
Rigel Pharmaceuticals (RIGL) Upgraded by BidaskClub to "Buy"Rigel Pharmaceuticals (RIGL) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - January 28 at 11:54 PM
Rigel Pharmaceuticals (RIGL) PT Set at $7.00 by HC WainwrightRigel Pharmaceuticals (RIGL) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - January 20 at 1:58 PM
Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 37.5% Annualized Using OptionsCommit To Purchase Rigel Pharmaceuticals At $2.50, Earn 37.5% Annualized Using Options
www.nasdaq.com - January 10 at 3:37 PM
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - PR Newswire (press release)Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - PR Newswire (press release)
www.prnewswire.com - January 6 at 3:37 PM
Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual JP ... - PR Newswire (press release)Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual JP ... - PR Newswire (press release)
www.prnewswire.com - January 5 at 3:39 PM
Rigel Pharmaceuticals, Inc. (RIGL) Given Average Rating of "Buy" by AnalystsRigel Pharmaceuticals, Inc. (RIGL) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 5 at 11:39 AM
Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare ConferenceRigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 11:16 AM
Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : January 1, 2018Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : January 1, 2018
finance.yahoo.com - January 1 at 11:07 AM
BidaskClub Upgrades Rigel Pharmaceuticals (RIGL) to SellBidaskClub Upgrades Rigel Pharmaceuticals (RIGL) to Sell
www.americanbankingnews.com - December 29 at 8:08 AM
Piper Jaffray Companies Initiates Coverage on Rigel Pharmaceuticals (RIGL)Piper Jaffray Companies Initiates Coverage on Rigel Pharmaceuticals (RIGL)
www.americanbankingnews.com - December 21 at 12:10 PM
Cantor Fitzgerald Weighs in on Rigel Pharmaceuticals, Inc.s FY2017 Earnings (RIGL)Cantor Fitzgerald Weighs in on Rigel Pharmaceuticals, Inc.'s FY2017 Earnings (RIGL)
www.americanbankingnews.com - December 20 at 7:20 AM
Rigel Pharmaceuticals (RIGL) Rating Lowered to Strong Sell at BidaskClubRigel Pharmaceuticals (RIGL) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - December 19 at 6:04 AM
Rigel Pharmaceuticals (RIGL) Stock Rating Lowered by ValuEngineRigel Pharmaceuticals (RIGL) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 16 at 3:36 PM
Rigel Pharma (RIGL) CFO Ryan Maynard Departs - StreetInsider.comRigel Pharma (RIGL) CFO Ryan Maynard Departs - StreetInsider.com
www.streetinsider.com - December 16 at 3:35 PM
Rigel Announces Departure of Chief Financial OfficerRigel Announces Departure of Chief Financial Officer
finance.yahoo.com - December 15 at 11:55 AM
Rigel Pharmaceuticals (RIGL) Coverage Initiated at Cantor FitzgeraldRigel Pharmaceuticals (RIGL) Coverage Initiated at Cantor Fitzgerald
www.americanbankingnews.com - December 14 at 7:06 PM
Short Interest in Rigel Pharmaceuticals, Inc. (RIGL) Expands By 26.5%Short Interest in Rigel Pharmaceuticals, Inc. (RIGL) Expands By 26.5%
www.americanbankingnews.com - December 13 at 1:10 AM
Rigel Pharmaceuticals, Inc. (RIGL) Given Consensus Rating of "Hold" by AnalystsRigel Pharmaceuticals, Inc. (RIGL) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 11 at 1:58 PM
Rigel Pharmaceuticals (RIGL) Given a $7.00 Price Target by HC Wainwright AnalystsRigel Pharmaceuticals (RIGL) Given a $7.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - December 11 at 8:30 AM
Rigel Pharma (RIGL) to Present One-Year Efficacy, Safety Results for Fostamatinib in ITP at ASH - StreetInsider.comRigel Pharma (RIGL) to Present One-Year Efficacy, Safety Results for Fostamatinib in ITP at ASH - StreetInsider.com
www.streetinsider.com - December 10 at 3:40 PM
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
www.prnewswire.com - December 8 at 8:49 PM
Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock OptionsImplied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
finance.yahoo.com - December 7 at 11:50 AM
Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : December 6, 2017Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : December 6, 2017
finance.yahoo.com - December 6 at 11:43 AM
ETFs with exposure to Rigel Pharmaceuticals, Inc. : December 5, 2017ETFs with exposure to Rigel Pharmaceuticals, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 3:36 PM
Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 5:01 PM
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire (press release)Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire (press release)
www.prnewswire.com - November 19 at 8:48 AM
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - November 18 at 11:22 AM
Rigel Pharmaceuticals, Inc. (RIGL) Receives Consensus Rating of "Hold" from BrokeragesRigel Pharmaceuticals, Inc. (RIGL) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 16 at 11:54 AM
Rigel Pharmaceuticals, Inc. (RIGL) Raised to "Buy" at Zacks Investment ResearchRigel Pharmaceuticals, Inc. (RIGL) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 11 at 6:30 AM
Rigel Pharmaceuticals, Inc. Expected to Post FY2017 Earnings of ($0.56) Per Share (RIGL)Rigel Pharmaceuticals, Inc. Expected to Post FY2017 Earnings of ($0.56) Per Share (RIGL)
www.americanbankingnews.com - November 10 at 1:54 PM
EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q3 Earnings Report
www.rttnews.com - November 9 at 12:33 PM
Rigel Pharmaceuticals, Inc. to Host Earnings CallRigel Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 12:33 PM
Rigel Pharmaceuticals, Inc. to Host Earnings CallRigel Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 12:33 PM
Rigel Announces Third Quarter 2017 Financial Results and Provides Company UpdateRigel Announces Third Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - November 9 at 12:33 PM
Rigel reports 3Q lossRigel reports 3Q loss
finance.yahoo.com - November 9 at 12:33 PM
Edited Transcript of RIGL earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of RIGL earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 9 at 12:33 PM
Equities Analysts Set Expectations for Rigel Pharmaceuticals, Inc.s Q1 2018 Earnings (RIGL)Equities Analysts Set Expectations for Rigel Pharmaceuticals, Inc.'s Q1 2018 Earnings (RIGL)
www.americanbankingnews.com - November 9 at 11:12 AM
Rigel Pharmaceuticals, Inc. (RIGL) CFO Ryan D. Maynard Sells 100,000 SharesRigel Pharmaceuticals, Inc. (RIGL) CFO Ryan D. Maynard Sells 100,000 Shares
www.americanbankingnews.com - November 8 at 12:22 AM
Rigel Pharmaceuticals, Inc. (RIGL) Announces  Earnings ResultsRigel Pharmaceuticals, Inc. (RIGL) Announces Earnings Results
www.americanbankingnews.com - November 7 at 9:28 PM
Rigel Pharmaceuticals, Inc. (RIGL) Receives New Coverage from Analysts at HC WainwrightRigel Pharmaceuticals, Inc. (RIGL) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - November 6 at 8:08 AM
Rigel Welcomes Gregg Lapointe to Board of DirectorsRigel Welcomes Gregg Lapointe to Board of Directors
finance.yahoo.com - November 4 at 11:43 AM
Rigel Pharmaceuticals, Inc. (RIGL) to Release Quarterly Earnings on TuesdayRigel Pharmaceuticals, Inc. (RIGL) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 1 at 8:08 PM
Rigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial ResultsRigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial Results
finance.yahoo.com - October 31 at 8:41 AM

SEC Filings

Rigel Pharmaceuticals (NASDAQ:RIGL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Rigel Pharmaceuticals (NASDAQ:RIGL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Rigel Pharmaceuticals (NASDAQ RIGL) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.